Safranal is a monoterpenoid that has been found in C. sativus and has diverse biological activities, including microtubule polymerization inhibitory, cancer cell growth inhibitory, and antioxidant properties.{61077,61078,61079,61080} It decreases microtubule polymerization in a cell-free assay (IC50 = 72.19 µM) and inhibits the growth of HeLa cells (IC50 = 95 µM).{61077,61078} Safranal (145.5, 363.75, and 727.5 mg/kg) reduces the levels of thiobarbituric acid reactive substances (TBARS) and malondialdehyde (MDA) in the hippocampus in a rat model of global cerebral ischemia.{61079} It also reduces convulsions induced by pentylenetetrazole (Item No. 18682) in mice.{61080}
Available on backorder
A monoterpenoid with microtubule polymerization inhibitory (IC50 = 72.19 µM), cancer cell growth inhibitory (IC50 = 95 µM for HeLa cells), and antioxidant properties; reduces TBARS and MDA levels in the hippocampus in a rat model of global cerebral ischemia at 145.5, 363.75, and 727.5 mg/kg
Formal name: 2,6,6-trimethyl-1,3-cyclohexadiene-1-carboxaldehyde
Synonyms:
Molecular weight: 150.2
CAS: 116-26-7
Purity: ≥98%
Formulation: A neat oil
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. (R)-Roscovitine is a potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM.{14988} It also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively.{14987,14988,14991} (R)-Roscovitine inhibits the growth of rapidly proliferating cells with an average IC50 value of 15.2 µM against a panel of 19 human tumor cell lines.{14988} In murine models of polycystic kidney disease, (R)-roscovitine effectively inhibited disease progression at doses of 50-100 mg/kg.{14564}
Available on backorder
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. (R)-Roscovitine is a potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM.{14988} It also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively.{14987,14988,14991} (R)-Roscovitine inhibits the growth of rapidly proliferating cells with an average IC50 value of 15.2 µM against a panel of 19 human tumor cell lines.{14988} In murine models of polycystic kidney disease, (R)-roscovitine effectively inhibited disease progression at doses of 50-100 mg/kg.{14564}
Available on backorder
1,2-Dipalmitoyl-sn-glycero-3-PC (DPPC) is a zwitterionic glycerophospholipid commonly used in the formation of lipid monolayers, bilayers, and liposomes for use in a variety of applications.{14480,24261,14478,14479} It has been used in the formation of proteoliposomes for implantation of γ-glutamyl transpeptidase into human erythrocyte membranes.{14478} Incorporation of glycosphingolipid antigens into DPPC-containing liposomes increases the immunogenicity of the antigens in mice.{14479}
Available on backorder
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. (R)-Roscovitine is a potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM.{14988} It also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively.{14987,14988,14991} (R)-Roscovitine inhibits the growth of rapidly proliferating cells with an average IC50 value of 15.2 µM against a panel of 19 human tumor cell lines.{14988} In murine models of polycystic kidney disease, (R)-roscovitine effectively inhibited disease progression at doses of 50-100 mg/kg.{14564}
Available on backorder